Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Oxford BioMedica plc    GB0006648157_GB   GB0006648157

OXFORD BIOMEDICA PLC (GB0006648157_GB)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (GBP)
Sales 2018 64,9 M
EBIT 2018 14,0 M
Net income 2018 12,5 M
Debt 2018 7,99 M
Yield 2018 -
Sales 2019 68,8 M
EBIT 2019 11,1 M
Net income 2019 9,16 M
Debt 2019 8,89 M
Yield 2019 -
P/E ratio 2018 43,83
P/E ratio 2019 60,37
EV / Sales2018 9,12x
EV / Sales2019 8,61x
Capitalization 584 M
More Financials
Company
Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy.The firm also provides bioprocessing and process development services to third parties.It operates through the Platform and Product segment.The Platform segment onsists of the... 
More about the company
Surperformance© ratings of Oxford BioMedica plc
Trading Rating : Investor Rating :
More Ratings
Latest news on OXFORD BIOMEDICA PLC
07/09BENITEC BIOPHARMA : Axovant deepens gene therapy pipeline with Benitec deal
AQ
06/08OXFORD BIOMEDICA : Axovant buys rights for Oxford BioMedicas Parkinsons candidat..
AQ
06/07OXFORD BIOMEDICA : Axovant Licenses Investigational Gene Therapy for Parkinsons ..
AQ
06/07OXFORD BIOMEDICA : Axovant reboots with gene therapy deal
AQ
06/07OXFORD BIOMEDICA : inks licensing agreement with Axovant Sciences
AQ
06/07OXFORD BIOMEDICA : Axovant pivots with new gene therapy, Spark co-founder as CTO
AQ
06/06OXFORD BIOMEDICA : and Axovant Sciences enter into a $842.5 Million Exclusive Wo..
BU
06/06OXFORD BIOMEDICA : and Axovant Sciences enter into a $842.5 Million Exclusive Wo..
PU
06/06OXFORD BIOMEDICA : Axovant Licenses Investigational Gene Therapy for Parkinson&r..
AQ
05/30OXFORD BIOMEDICA PLC : REVERSE SPLIT: 1 of 50
FA
More news
Sector news : Bio Therapeutic Drugs
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
03/16Oxford Biomedica PLC 2017 Q4 - Results - Earnings Call Slides 
2017Oxford Biomedica PLC reports 1H results 
2017The CTL019 Adcom Mists Begin To Clear 
2017Oxford BioMedica (OXBDF) Presents At Jefferies 2017 Global Healthcare Confere.. 
2017SNIPPET ROUNDUP : Novartis' Allogeneic CAR-T Drive And Astra's IL-4 Interest 
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 10,4  GBP
Spread / Average Target 25%
EPS Revisions
Managers
NameTitle
John Dawson Chief Executive Officer & Executive Director
Lorenzo M. Tallarigo Non-Executive Chairman
Nick Page Chief Operating Officer
Stuart Paynter Chief Financial Officer & Director
Kyriacos Mitrophanous Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
OXFORD BIOMEDICA PLC0.00%773
GILEAD SCIENCES7.84%100 614
VERTEX PHARMACEUTICALS20.45%45 997
REGENERON PHARMACEUTICALS-2.21%38 951
GENMAB5.93%10 467
NEUROCRINE BIOSCIENCES, INC.32.61%9 250